| scholarly article | Q13442814 |
| P356 | DOI | 10.1001/JAMADERMATOL.2013.4200 |
| P698 | PubMed publication ID | 23699661 |
| P50 | author | Eric Deutsch | Q56528951 |
| Yungan Tao | Q56650271 | ||
| Lise Boussemart | Q64683121 | ||
| P2093 | author name string | Caroline Robert | |
| Christine Mateus | |||
| Emilie Routier | |||
| Joël Claveau | |||
| Gorana Tomasic | |||
| Catherine Boivin | |||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 855-857 | |
| P577 | publication date | 2013-07-01 | |
| P1433 | published in | JAMA Dermatology | Q3918707 |
| P1476 | title | Vemurafenib and radiosensitization | |
| P478 | volume | 149 |
| Q35820476 | A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases. |
| Q26744148 | Acute and Chronic Cutaneous Reactions to Ionizing Radiation Therapy |
| Q48472127 | An acneiform eruption exhibiting locus minoris resistentiae after whole-brain radiation and vemurafenib therapy |
| Q28079359 | Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG) |
| Q28076667 | BRAF inhibitors and radiotherapy for melanoma brain metastases: potential advantages and disadvantages of combination therapy |
| Q38281838 | BRAF inhibitors: experience in thyroid cancer and general review of toxicity |
| Q38844399 | Combination of Radiotherapy and Targeted Agents in Brain Metastasis: An Update |
| Q55054189 | Cutaneous Papillomaviruses and Non-melanoma Skin Cancer: Causal Agents or Innocent Bystanders? |
| Q28070095 | Cutaneous complications of molecular targeted therapy used in oncology |
| Q53118960 | Eccrine squamous syringometaplasia in sites of radiation recall secondary to vemurafenib therapy for BRAF-mutated carcinoma. |
| Q38598521 | Evolving treatment options for melanoma brain metastases |
| Q40203106 | Increased skin and mucosal toxicity in the combination of vemurafenib with radiation therapy |
| Q41677075 | LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases |
| Q34403517 | Localized Epidermal Cysts as a Radiation Recall Phenomenon in a Melanoma Patient Treated with Radiotherapy and the BRAF Inhibitor Vemurafenib |
| Q38807942 | Melanoma central nervous system metastases: current approaches, challenges, and opportunities |
| Q30838330 | On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases. |
| Q87420667 | Radiation recall dermatitis after docetaxel chemotherapy. Treatment by antioxidant ointment |
| Q38747046 | Radiation recall dermatitis induced by sorafenib : A case study and review of the literature |
| Q38166905 | Radiation therapy for advanced and metastatic melanoma |
| Q38652041 | Radiotherapy with BRAF inhibitor therapy for melanoma: progress and possibilities |
| Q41346638 | Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma |
| Q49956245 | Targeted therapy of brain metastases: latest evidence and clinical implications |
| Q26744335 | The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinib |
| Q38203019 | The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutation |
| Q37632230 | Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications |
| Q45150448 | Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib. Two case reports |
| Q35967342 | Vemurafenib and cutaneous adverse events--report of five cases |
| Q43868871 | What's new in clinical dermatology? |
| Q53063698 | [Cutaneous side effects of anti-tumor therapy with BRAF and MEK inhibitors]. |
Search more.